EMA Authorised: Isentress (raltegravir) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA has authorised Isentress (raltegravir) for HIV infections; decision dated 12 November 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 12/11/2025. Accelerated assessment